Tumor sampling

PROCEDURE4 trials

Sponsors

Institut Paoli-Calmettes, Institut Curie, Pietro Mortini, MD, Prof., Assistance Publique - Hôpitaux de Paris

Conditions

Brain Tumor - MetastaticBrain Tumor, PrimaryCancerGlioblastoma (GBM)Leukemia, Myeloid, Acute

Unknown Phase

ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia

Institut Paoli-CalmettesLeukemia, Myeloid, Acute

Start: 2015-08-31End: 2017-08-31Target: 87Updated: 2016-06-28

Analysis of Circulating Tumor Markers in the Blood (ALCINA)

CompletedNCT02866149

Institut CurieCancer

Start: 2015-07-31End: 2024-09-30Updated: 2024-10-01

Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors

RecruitingNCT05831631

Pietro Mortini, MD, Prof.Brain Tumor - Metastatic, Brain Tumor, Primary

Start: 2022-08-01End: 2029-08-01Target: 200Updated: 2025-06-11

Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas

Not yet recruitingNCT07472387

Assistance Publique - Hôpitaux de ParisGlioblastoma (GBM)

Start: 2026-04-01End: 2030-04-01Target: 40Updated: 2026-03-16

Related Papers

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.

2024-10-1415 citations

Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis

Oncogene2024-02-2717 citations

Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer

British Journal of Cancer2023-11-1636 citations

Abstract P5-02-19: ctDNA as dynamic marker of response to fulvestrant and everolimus in CDK4/6 inhibitor-pretreated ER+ HER2- metastatic breast cancer patients: a prospective study

Cancer Research2023-03-012 citations

Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer

Clinical Chemistry2021-06-2882 citations

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

Breast Cancer Research2020-09-1428 citations

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.

2020-06-0318 citations

Plasma-derived cfDNA to reveal potential biomarkers of response prediction and monitoring in non-small cell lung cancer (NSCLC) patients on immunotherapy.

Journal of Clinical Oncology2020-05-20

Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer

Clinical Chemistry2020-05-1949 citations

Abstract P5-01-12: Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy

Cancer Research2020-02-15

Immune-related toxicities in non-small cell lung cancer: Real-life predictors of outcome to checkpoint inhibitors?

Journal of Clinical Oncology2019-05-201 citations

Abstract P4-01-20: Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer

Cancer Research2019-02-15

Baseline blood immune profiling to predict response to antiPD-1 in patients with advanced non-small cell lung cancer

Annals of Oncology2018-10-01

Abstract 4589: Expression of PD-L1 on circulating breast cancer cells: Correlation with clinicopathologic data and impact on prognosis

Cancer Research2018-07-014 citations